NCT03974594View on ClinicalTrials.gov

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2019

Conditions
Colorectal Cancer
Interventions
DRUG

Trifluridine and Tipiracil Tablets

Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle

DRUG

TAS-102

TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle

Trial Locations (1)

710038

Tangdu Hospital,Fourth Military Medical University, Xi’an

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY